.Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AL10_FormoterolAndTiotropiumB.FormoterolAndTiotropiumB .Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AL10_FormoterolAndTiotropiumB.FormoterolAndTiotropiumB| name: | FormoterolAndTiotropiumBromide |
| ATC code: | R03AL10 | route: | inhaled |
| n-compartments | 2 |
Formoterol and tiotropium bromide is a fixed-dose combination inhaler containing a long-acting beta2-adrenergic agonist (formoterol) and a long-acting muscarinic antagonist (tiotropium). It is used as a maintenance treatment of chronic obstructive pulmonary disease (COPD) to improve airflow and reduce exacerbations. This combination is approved and used in clinical practice today.
Pharmacokinetic parameters estimated for adults with COPD following inhaled administration of fixed-dose combination formoterol and tiotropium bromide. No dedicated population PK model publication for the fixed combination was found; approximate parameters referenced are based on known single-agent PKs and inhaled route estimates.
Deeks, ED (2015). Olodaterol: a review of its use in chronic obstructive pulmonary disease. Drugs 75(6) 665–673. DOI:10.1007/s40265-015-0371-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25773742